78.77
1.36 (1.76%)
| Previous Close | 77.40 |
| Open | 77.37 |
| Volume | 246,092 |
| Avg. Volume (3M) | 628,309 |
| Market Cap | 2,163,784,704 |
| Price / Sales | 7.65 |
| Price / Book | 10.39 |
| 52 Weeks Range | |
| Earnings Date | 18 Feb 2025 - 24 Feb 2025 |
| Profit Margin | -31.25% |
| Operating Margin (TTM) | -10.11% |
| Diluted EPS (TTM) | -3.09 |
| Quarterly Revenue Growth (YOY) | 44.20% |
| Total Debt/Equity (MRQ) | 56.77% |
| Current Ratio (MRQ) | 2.40 |
| Operating Cash Flow (TTM) | -55.17 M |
| Levered Free Cash Flow (TTM) | -20.06 M |
| Return on Assets (TTM) | -8.27% |
| Return on Equity (TTM) | -36.40% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Mixed | Bearish |
| Health Information Services (Global) | Mixed | Bearish | |
| Stock | GeneDx Holdings Corp. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | -1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -1.10 |
|
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Growth |
| % Held by Insiders | 18.19% |
| % Held by Institutions | 72.00% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Casdin Capital, Llc | 30 Sep 2024 | 3,507,164 |
| Corvex Management Lp | 30 Sep 2024 | 2,473,781 |
| Oracle Investment Management Inc | 30 Sep 2024 | 1,045,768 |
| Gagnon Securities Llc | 30 Sep 2024 | 541,943 |
| Blackstone Inc. | 30 Sep 2024 | 420,715 |
| Fred Alger Management, Llc | 30 Sep 2024 | 394,230 |
| Point72 Asset Management, L.P. | 30 Sep 2024 | 293,671 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (Craig-Hallum, 20.61%) | Buy |
| Median | 75.00 (-4.78%) | |
| Low | 70.00 (Goldman Sachs, -11.13%) | Hold |
| Average | 80.00 (1.57%) | |
| Total | 1 Buy, 2 Hold | |
| Avg. Price @ Call | 83.20 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 30 Oct 2024 | 95.00 (20.61%) | Buy | 83.20 |
| 24 Oct 2024 | 70.00 (-11.13%) | Buy | 59.09 | |
| Goldman Sachs | 30 Oct 2024 | 70.00 (-11.13%) | Hold | 83.20 |
| 16 Oct 2024 | 54.00 (-31.44%) | Hold | 60.78 | |
| Wells Fargo | 30 Oct 2024 | 75.00 (-4.78%) | Hold | 83.20 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FEELEY KEVIN | - | 80.50 | -3,728 | -300,104 |
| STUELAND KATHERINE | - | 80.50 | -10,501 | -845,331 |
| Aggregate Net Quantity | -14,229 | |||
| Aggregate Net Value ($) | -1,145,435 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 80.50 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FEELEY KEVIN | Officer | 16 Dec 2024 | Sell (-) | 3,728 | 80.50 | 300,104 |
| FEELEY KEVIN | Officer | 16 Dec 2024 | Option execute | 7,197 | - | - |
| STUELAND KATHERINE | Officer | 16 Dec 2024 | Sell (-) | 10,501 | 80.50 | 845,331 |
| STUELAND KATHERINE | Officer | 16 Dec 2024 | Option execute | 18,750 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |